OBJECTIVE: To examine the association of hospital volume and 90-day mortality after cystectomy, conditional on survival for 30 days. PATIENTS AND METHODS: The National Cancer Data Base was used to evaluate 30- and 90-day mortality for 35,055 patients who underwent cystectomy for bladder cancer at one of 1118 hospitals. Patient data were aggregated into hospital volume categories based on the mean annual number of procedures (low-volume hospital: <10 procedures; intermediate-volume hospital: 10-19 procedures; high-volume hospital: ≥20 procedures). Associations between mortality and clinical, demographic and hospital characteristics were analysed using hierarchical logistic regression models. To assess the association between hospital volume and 90-day mortality independently of shorter-term mortality, 90-day mortality conditional on 30-day survival was assessed in the multivariate modelling. RESULTS: Unadjusted 30- and 90-day mortality rates were 2.7 and 7.2% overall, 1.9 and 5.7% among high-volume hospitals, and 3.2 and 8.0% among low-volume hospitals, respectively. Compared with high-volume hospitals, the adjusted risks among low-volume hospitals (odds ratio [95% CI]) of 30- and 90-day mortality, conditional on having survived for 30 days, from the hierarchical models were 1.5 (1.3-1.9), and 1.2 (1.0-1.4), respectively. CONCLUSIONS: A low hospital volume was associated with greater 30- and 90-day mortality. These data support the need for further research to better understand the relatively high mortality rates seen between 30 and 90 days, which are high and less variable across hospital volume strata. The stronger association between volume and 30-day mortality suggests that quality-reporting efforts should focus on shorter-term outcomes.
OBJECTIVE: To examine the association of hospital volume and 90-day mortality after cystectomy, conditional on survival for 30 days. PATIENTS AND METHODS: The National Cancer Data Base was used to evaluate 30- and 90-day mortality for 35,055 patients who underwent cystectomy for bladder cancer at one of 1118 hospitals. Patient data were aggregated into hospital volume categories based on the mean annual number of procedures (low-volume hospital: <10 procedures; intermediate-volume hospital: 10-19 procedures; high-volume hospital: ≥20 procedures). Associations between mortality and clinical, demographic and hospital characteristics were analysed using hierarchical logistic regression models. To assess the association between hospital volume and 90-day mortality independently of shorter-term mortality, 90-day mortality conditional on 30-day survival was assessed in the multivariate modelling. RESULTS: Unadjusted 30- and 90-day mortality rates were 2.7 and 7.2% overall, 1.9 and 5.7% among high-volume hospitals, and 3.2 and 8.0% among low-volume hospitals, respectively. Compared with high-volume hospitals, the adjusted risks among low-volume hospitals (odds ratio [95% CI]) of 30- and 90-day mortality, conditional on having survived for 30 days, from the hierarchical models were 1.5 (1.3-1.9), and 1.2 (1.0-1.4), respectively. CONCLUSIONS: A low hospital volume was associated with greater 30- and 90-day mortality. These data support the need for further research to better understand the relatively high mortality rates seen between 30 and 90 days, which are high and less variable across hospital volume strata. The stronger association between volume and 30-day mortality suggests that quality-reporting efforts should focus on shorter-term outcomes.
Authors: John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg Journal: N Engl J Med Date: 2002-04-11 Impact factor: 91.245
Authors: Brent K Hollenbeck; David C Miller; David A Taub; Rodney L Dunn; Shukri F Khuri; William G Henderson; James E Montie; Willie Underwood; John T Wei Journal: J Urol Date: 2006-10 Impact factor: 7.450
Authors: Linda S Elting; Curtis Pettaway; B Nebiyou Bekele; H Barton Grossman; Catherine Cooksley; Elenir B C Avritscher; Kamaldeen Saldin; Colin P N Dinney Journal: Cancer Date: 2005-09-01 Impact factor: 6.860
Authors: Jerome H Liu; David S Zingmond; Marcia L McGory; Nelson F SooHoo; Susan L Ettner; Robert H Brook; Clifford Y Ko Journal: JAMA Date: 2006-10-25 Impact factor: 56.272
Authors: Brent K Hollenbeck; David A Taub; David C Miller; Rodney L Dunn; James E Montie; John T Wei Journal: J Urol Date: 2005-10 Impact factor: 7.450
Authors: John D Birkmeyer; Therese A Stukel; Andrea E Siewers; Philip P Goodney; David E Wennberg; F Lee Lucas Journal: N Engl J Med Date: 2003-11-27 Impact factor: 91.245
Authors: Oyewale O Shiyanbola; Brian L Sprague; John M Hampton; Kim Dittus; Ted A James; Sally Herschorn; Ronald E Gangnon; Donald L Weaver; Amy Trentham-Dietz Journal: Cancer Date: 2016-05-31 Impact factor: 6.860
Authors: Sebastian Karl Frees; Jonathan Aning; Peter Black; Werner Struss; Robert Bell; Claudia Chavez-Munoz; Martin Gleave; Alan I So Journal: World J Urol Date: 2017-11-07 Impact factor: 4.226
Authors: Meera R Chappidi; Max Kates; C J Stimson; Michael H Johnson; Phillip M Pierorazio; Trinity J Bivalacqua Journal: J Urol Date: 2016-08-18 Impact factor: 7.450
Authors: Jeffrey J Leow; Jens Bedke; Karim Chamie; Justin W Collins; Siamak Daneshmand; Petros Grivas; Axel Heidenreich; Edward M Messing; Trevor J Royce; Alexander I Sankin; Mark P Schoenberg; William U Shipley; Arnauld Villers; Jason A Efstathiou; Joaquim Bellmunt; Arnulf Stenzl Journal: World J Urol Date: 2019-01-25 Impact factor: 4.226
Authors: Noam A VanderWalde; Michelle T Chi; Arti Hurria; Matthew D Galsky; Matthew E Nielsen Journal: World J Urol Date: 2015-10-23 Impact factor: 4.226